FindTrial
Sign In

Research on the Association between rs5911, rs5787 and rs3842788 Gene Polymorphisms and Aspirin Resistance in Coronary Heart Disease Patients

Research on the Association between Aspirin Resistance, rs5911, rs5787 and rs3842788 Gene Polymorphisms, and the Effect of Activating Blood and Removing Stasis Herbs

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OCC-12002415
Enrollment
Unknown
Registered
2012-08-10
Start date
2012-08-28
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease (CHD)

Interventions

Non-aspirin resistance group:Conventional treatment

Sponsors

Xiyuan Hospital, China Academy of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Stable angina: (Chinese Journal of Cardiology. 2007; 35: 159-206); 2. Aged 35 to 75 years old; 3. Have taken aspirin for more than 7 days.

Exclusion criteria

Exclusion criteria: 1. Aspirin allergy; 2. Family or personal history of bleeding disorders; 3. platelet count450*10^9/L; 4. Hemoglobin <90 g/L; 5. Have taken other antiplatelet, anticoagulant drugs or non-steroidal anti-inflammatory drugs, that may affect platelet aggregation, such as clopidogrel, ticlopidine, warfarin or heparin in latest two weeks; 6. Have taken activating blood and removing stasis herbs in latest two weeks; 7. History of trauma or surgery in latest two weeks; 8. With severe primary diseases of hepatic, renal, hematopoietic and nervous system, mental disorder or malignant tumor; 9. Woman in Pregnancy, or lactation period.

Design outcomes

Primary

MeasureTime frame
Gene polymorphisms;Platelet aggregation rate;—

Countries

China

Contacts

Public ContactMei Xue
meiar@126.com+86 13581801296

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026